When to Refer Patients for Left Atrial Appendage Closure

Area of Science:

• Cardiology
• Interventional Cardiology
• Medical Devices

Background:

• Nonvalvular atrial fibrillation (NVAF) necessitates anticoagulation to prevent stroke.
• Oral anticoagulants carry bleeding risks and compliance challenges for some patients.
• Left atrial appendage closure (LAAC) devices offer an alternative stroke prevention strategy.

Purpose of the Study:

• To outline criteria for referring NVAF patients for LAAC device implantation.
• To review clinical scenarios and indications for LAAC based on regulatory approvals.
• To discuss factors influencing LAAC device and patient selection.

Main Methods:

• Review of FDA-approved indications for LAAC devices.
• Analysis of clinical scenarios favoring LAAC over or alongside oral anticoagulation.
• Consideration of patient-specific factors like bleeding risk and prognosis.

Main Results:

• LAAC referral decisions should integrate bleeding risk, anticoagulation compliance, and patient preferences.
• Specific clinical scenarios, aligned with FDA indications, guide LAAC consideration.
• European indications for LAAC differ from FDA approvals.

Conclusions:

• LAAC is a viable stroke prevention option for select NVAF patients.
• Careful patient selection and understanding of indications are crucial for successful LAAC.
• Evolving clinical trials and device technology will further refine LAAC use and post-implant management.